ストックスクリーナーアプリを入手
13.15
2.41%
0.31
アフターアワーズ：
13.15
前日終値:
$12.84
開ける：
$13.08
24時間の取引高:
297.19K
Relative Volume:
1.38
時価総額：
$442.72M
収益：
$99.99M
当期純損益:
$-21.47M
株価収益率:
-19.93
EPS:
-0.6597
ネットキャッシュフロー:
$-11.34M
1週間 パフォーマンス:
-0.90%
1か月 パフォーマンス:
-9.81%
6か月 パフォーマンス:
+27.55%
1年 パフォーマンス:
+7.00%
1日の値動き範囲:
$12.47
$13.28
1週間の範囲:
$12.47
$13.73
52週間の値動き範囲:
$7.5625
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
13.15 | 432.28M | 99.99M | -21.47M | -11.34M | -0.6597 |
ABT
Abbott Laboratories
|
102.67 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.59 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.65 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.75 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-28 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-21 | 開始されました | UBS | Buy |
| 2024-03-14 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | 開始されました | Leerink Partners | Outperform |
| 2023-11-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-08-24 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | 開始されました | Lake Street | Buy |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | 開始されました | Robert W. Baird | Outperform |
| 2021-05-17 | 開始されました | JP Morgan | Overweight |
| 2021-05-17 | 開始されました | Morgan Stanley | Overweight |
| 2021-05-17 | 開始されました | SVB Leerink | Outperform |
| 2021-05-17 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Neuropace Inc (NPCE) 最新ニュース
NeuroPace (NPCE) CMO has 1,341 shares withheld for RSU tax - Stock Titan
Aug Selloffs: What makes NeuroPace Inc stock attractive todayMarket Weekly Review & Weekly High Momentum Picks - baoquankhu1.vn
Director at NeuroPace (NPCE) receives 913-share stock grant and controls large fund stake - Stock Titan
NeuroPace director granted 865 shares at $13 | NPCE Insider Trading - Stock Titan
NeuroPace (NPCE) director gets 1,153-share stock grant as board fees - Stock Titan
NeuroPace (NPCE) director receives 1,826-share equity grant in lieu of cash fees - Stock Titan
NeuroPace, Inc. (NPCE) may report negative earnings: Know the trend ahead of next week's release - MSN
Discipline and Rules-Based Execution in NPCE Response - Stock Traders Daily
Analysts Are Bullish on These Healthcare Stocks: Kestra Medical Technologies Ltd. (KMTS), NeuroPace (NPCE) - The Globe and Mail
NeuroPace (NASDAQ:NPCE) Upgraded at Wells Fargo & Company - MarketBeat
Wells Fargo Upgrades NeuroPace(NPCE.US) to Buy Rating, Raises Target Price to $19 - Moomoo
How The NeuroPace (NPCE) Story Is Shifting As Analysts Refresh Valuation Assumptions - Yahoo Finance
NeuroPace (NASDAQ:NPCE) Stock Rating Lowered by Wall Street Zen - MarketBeat
NPCE SEC FilingsNeuropace Inc 10-K, 10-Q, 8-K Forms - Stock Titan
NeuroPace falls after setback in trial for neuromodulation system - MSN
Published on: 2026-03-12 04:41:05 - baoquankhu1.vn
NeuroPace at Leerink Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
Key Factors Expected to Influence NPCE Stock Performance in 2026 - Bitget
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026 - TradingView
NPCE RNS System Explained: Growth Drivers and Setup for 2026 - TradingView
NeuroPace's Seizure ID and New Indication Could Expand RNS Demand - Yahoo Finance
Neuropace (NPCE) chief medical officer sells $399k in stock - Investing.com Nigeria
Behavioral Patterns of NPCE and Institutional Flows - Stock Traders Daily
Published on: 2026-03-09 06:34:24 - baoquankhu1.vn
NeuroPace appoints Patrick Williams as CFO - MSN
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Market Outlook: Will NeuroPace Inc stock benefit from M AJuly 2025 Technicals & Technical Buy Zone Confirmation - baoquankhu1.vn
NeuroPace (NASDAQ:NPCE) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Rate Cut: Will NeuroPace Inc stock benefit from M AEarnings Recap Summary & Long Hold Capital Preservation Plans - baoquankhu1.vn
Gains Recap: Is NeuroPace Inc a stock for growth or value investorsJuly 2025 WrapUp & Community Trade Idea Sharing - baoquankhu1.vn
Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access - The Globe and Mail
NeuroPace to Present at the Leerink Global Healthcare Conference - Investing News Network
NeuroPace revenue up 24% to USD 26.6M in Q4 2025 - Medical Buyer
Boston Scientific to buy Penumbra in $14.5 billion deal - AOL.com
NeuroPace (NASDAQ:NPCE) Stock Rating Upgraded by Cantor Fitzgerald - MarketBeat
NeuroPace (NPCE) Loss Narrowing In Q4 Tests Bullish Profitability Narrative - simplywall.st
NeuroPace (NPCE) CMO sells shares under Rule 10b5-1 trading plan - Stock Titan
NeuroPace (NPCE) CEO reports 5,023-share tax-withholding disposition on RSU vesting - Stock Titan
Why NeuroPace Stock Was Inching Higher on Wednesday - AOL.com
Why NeuroPace Stock Was Inching Higher on Wednesday - The Motley Fool
NeuroPace (NPCE) Q4 2025 Earnings Call Transcript - The Globe and Mail
NeuroPace beats estimates as Q4 revenue surges 24%, sending shares up 15% By Investing.com - Investing.com South Africa
NeuroPace Q4 Earnings Call Highlights - MarketBeat
NeuroPace Beats Q1 Earnings Estimates - National Today
Earnings call transcript: Neuropace beats Q4 2025 EPS forecast, stock dips - Investing.com Nigeria
NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates - Nasdaq
Neuropace earnings beat by $0.10, revenue topped estimates - Investing.com Canada
NeuroPace : Investor Presentation - marketscreener.com
Neuropace Inc (NPCE) 財務データ
収益
当期純利益
現金流量
EPS
2.03%
大文字化:
|
ボリューム (24 時間):